Skip to main content
    A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.31
    -0.05 (-0.60%)

    Market Cap: $240.96M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcturus Therapeutics Holdings Inc (ARCT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Arcturus Therapeutics Holdings (ARCT) to earn -$2.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $28.35M. Of 13 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 85% of the ratings.

    RatingAnalystsShare
    Strong Buy17.7%
    Buy1076.9%
    Hold215.4%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 6.1%.

    Fiscal year ending Dec 31, 2026
    -$2.90
    EPS consensus, revenue $28.35M
    Fiscal year ending Dec 31, 2027
    -$3.33
    EPS consensus, revenue $30.09M
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.90-$3.01 to -$2.737$28.35M$24.50M to $33.52M9
    Dec 31, 2027-$3.33-$4.38 to -$1.9910$30.09M$3.00M to $127.81M13

    Quarterly Estimates

    The EPS consensus rises from -$0.92 for the quarter ending Dec 31, 2026 to -$0.88 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.92-$1.52 to -$0.5515$5.22M$1.42M to $20.72M15
    Mar 31, 2027-$0.88-$1.05 to -$0.764$1.95M$600000 to $3.83M5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202731
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.34.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.90-$3.45-$3.42-$3.42-$3.34N/A
    Fiscal year ending Dec 31, 2027-$3.33-$3.70-$3.62-$3.61-$3.83N/A
    Quarter ending Mar 31, 2027-$0.88-$0.83-$0.83-$0.83-$0.96N/A

    Frequently Asked Questions About ARCT

    What is the ARCT stock forecast?

    Consensus analyst estimates put Arcturus Therapeutics Holdings's EPS at -$2.90 for the fiscal year ending Dec 31, 2026, on revenue of $28.35M. The consensus rating from 13 analysts is Buy.

    How do analysts rate ARCT stock?

    Of 13 analysts covering Arcturus Therapeutics Holdings, 1 rates it Strong Buy, 10 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ARCT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.90, with estimates from -$3.01 to -$2.73 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.33, with estimates from -$4.38 to -$1.99 from 10 analysts.

    What revenue do analysts expect from Arcturus Therapeutics Holdings next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $28.35M, with estimates from $24.50M to $33.52M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $30.09M, with estimates from $3.00M to $127.81M.

    How many analysts cover ARCT?

    13 analysts rate Arcturus Therapeutics Holdings stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.